Institute for Cancer Research


Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.

The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.

Harald Stenmark<br>Acting Inst. Head
Harald Stenmark
Acting Inst. Head

Scientific production - Institute for Cancer Research

  Publications Doctoral theses
2017 so far  
 2016 235  
2015 221 21
2014 174 25
2013 205 27

Annual report 2015 (pdf format)


Latest news

OUH research seminar, Tuesday, April 25th 10:00 - 15:45

Immunotherapy for Cancer


Welcome to the next Oslo University Hospital research seminar entitled "Immunotherapy for Cancer".

Time: Tuesday, April 25th, 2017, at 10:00-15:45.
Place: Store Auditorium, Rikshospitalet, Sognsvannsveien 20, Oslo.

Note that there is a limited number of seats. Please sign up at:


Study on replication fork stability from Skarstad group published in Nucleic Acids Research

First authors Ida B. Pedersen (left) and Emily Helgesen
First authors Ida B. Pedersen (left) and Emily Helgesen

Replication forks must be stabilized in order to avoid DNA breakage and recombination. In a study recently published in Nucleic Acids Research entitled “SeqA structures behind Escherichia coli replication forks affect replication elongation and restart mechanisms“ researchers in the Skarstad group show that double strand breaks are generated in the absence of fork-trailing SeqA structures and that cells then have lost the ability to perform direct (RecA-independent) restart of replication forks. The two first authors are Ida Benedikte Pedersen and Emily Helgesen (photo).


The AACR-WICR Friend Lectureship presented to Anne-Lise Børresen-Dale

A-L. Børresen-Dale
A-L. Børresen-Dale

The American Association for Cancer Research (AACR) - Women in Cancer Research (WICR) Charlotte Friend Memorial Lectureship was established in 1998 in honour of renowned virologist and discoverer of the Friend virus, Dr. Charlotte Friend. The WICR Friend Lectureship is presented to an outstanding scientist who has made meritorious contributions to the field of cancer research and who has, through leadership or by example, furthered the advancement of women in science.
Anne-Lise Børresen-Dale, professor emerita at the Department of Cancer Genetics at the Institute for Cancer Research, OUH, has been chosen as the 20th Annual Award Recipient. Her award lecture will be held on April 3rd in the Washington Convention Center.


A retrospective pooled biomarker study to predict overall survival beyond the TNM system

Researchers Stine Aske Danielsen and Anita Sveen.
Researchers Stine Aske Danielsen and Anita Sveen.

K.G.Jebsen Colorectal Cancer Research Centre scientists participated with data from patients admitted to OUH in a multicenter study of >7000 stage II and III CRC recently reported in Annals of Oncology (Dienstmann et al).
Incorporation of MSI, BRAFV600E and KRAS mutation status to overall survival models with TNM staging improves the ability to precisely prognosticate in stage II and III CC patients, but only modestly increases prediction accuracy in multivariable models that include clinicopathological features, particularly in chemotherapy-treated patients.


CanCell – a new Centre of Excellence – will reprogram cancer cells


“Centre for Cancer Cell Reprogramming”, affiliated with the Institute of Clinical Medicine at University of Oslo, has been funded by the Research Council of Norway as a new Centre of Excellence.


New group leader at the Institute for Cancer Research:

Jørgen Wesche appointed group leader for the Mesenchymal Cancer Biology Group at the Department of Tumor Biology

Jørgen Wesche
Jørgen Wesche

Jørgen Wesche earned his PhD in Sjur Olsnes's group in 2001, studying intracellular transport and membrane translocation. During his postdoctoral training, spending some time at Institute Curie in Paris, he has changed his focus towards problems with more translational relevance, specializing in live cell imaging, fibroblast growth factor receptor (FGFR) signaling and importance of FGFR in cell migration/invasion. Aberrations in FGFR signaling are found in several types of sarcoma and that´s the main reason way Jørgen started to get interested in sarcoma biology and treatment. He has several exciting ideas on how to further develop his research into more translational/clinical relevance.